Wnt+ adipocytes, exosomes from wnt+ adipocytes, and methods of making and using them
US-2024058390-A1 · Feb 22, 2024 · US
Exosomes from human adipose-derived stem cells for the treatment of brain injury
US10857187B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10857187-B2 |
| Application number | US-201816011239-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 18, 2018 |
| Priority date | Jun 16, 2017 |
| Publication date | Dec 8, 2020 |
| Grant date | Dec 8, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Brain injury can be caused by trauma or may occur in stroke or neurodegenerative diseases. The disclosure relates to compositions that can include exosomes isolated from human adipose-derived stem cells (hASC) and methods where exosomes from hASC may be used alone or in combination with insulin for the treatment of brain injury.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a traumatic brain injury in a subject, the method comprising intranasally or intravenously administering to the subject a composition comprising exosomes isolated from human adipose-derived stem cells (hASCs), wherein the isolated exosomes comprise metastasis associated lung adenocarcinoma transcript 1/nuclear-enriched abundant transcript 2 (MALAT1/NEAT2) long noncoding RNA, and wherein the method of treating a traumatic brain injury results in increased neuronal functioning. 2. The method of claim 1 , wherein the composition further comprises insulin. 3. The method of claim 1 , wherein the method further comprises administering insulin to the subject. 4. The method of claim 3 , wherein the insulin is administered to the subject separately from the composition comprising isolated exosomes. 5. The method of claim 1 , wherein the subject is a mammal. 6. The method of claim 1 , wherein the subject is a human. 7. The method of claim 1 , wherein administering to the subject comprises intravenous administration. 8. The method of claim 1 , wherein administering to the subject comprises intranasal administration. 9. The method of claim 1 , wherein the traumatic brain injury comprises a diffuse axonal injury, a concussion, a contusion, a coup-countrecoup injury, a recurrent traumatic brain injury, combinations thereof. 10. The method of claim 1 , wherein the treating of a traumatic brain injury results in increased proliferation and survival of neurons. 11. The method of claim 1 , wherein the treating of a traumatic brain injury results in increased motor function. 12. The method of claim 1 , wherein the treating of a traumatic brain injury results in decreased cortical lesion volume.
Assignees
Inventors
Classifications
Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title
Insulins · CPC title
with ribosyl as saccharide radical · CPC title
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title
- A61K35/35Primary
Fat tissue; Adipocytes; Stromal cells; Connective tissues (adipose-derived stem cells A61K35/28; collagen A61K38/39) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10857187B2 cover?
- Brain injury can be caused by trauma or may occur in stroke or neurodegenerative diseases. The disclosure relates to compositions that can include exosomes isolated from human adipose-derived stem cells (hASC) and methods where exosomes from hASC may be used alone or in combination with insulin for the treatment of brain injury.
- Who is the assignee on this patent?
- Patel Niketa A, Bickford Paula Cole, Univ South Florida
- What technology area does this patent fall under?
- Primary CPC classification A61K35/35. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).